Cost-Utility Analysis of the Treatment With Ataluren Plus Standard of Care Compared With Standard of Care Alone in Patients With Duchenne Muscular Dystrophy in Brazil
Ataluren plus SoC for treating nonsense mutation Duchenne muscular dystrophy patients was not a cost-effective intervention compared with SoC alone from the perspective of the Brazilian public health system.
Authors
- Eliane Würdig Roesch (ORCID: https://orcid.org/0000-0002-9507-6344)
- Cátia Cristina Martins de Oliveira (ORCID: https://orcid.org/0000-0002-6419-7506)
- Verônica Colpani (ORCID: https://orcid.org/0000-0002-7908-4213)
- Henry M. Peixoto
- Klébya Hellen D. de Oliveira
- Ana Flávia de M. Oliveira
- Grace Anne A. Dória
Institutions
- Universidade de Brasília (BR)
- Universidade Federal de Sergipe (BR)
- Instituto Federal do Tocantins (BR)
- Hospital Sírio-Libanês (BR)
- Fundação Oswaldo Cruz (BR)
Publication Details
- Journal
- Value in Health Regional Issues
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.vhri.2026.101623
- Primary Topic
- Muscle Physiology and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00